Stock INZY INOZYME PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Inozyme Pharma, Inc. Stock

Equities

INZY

US45790W1080

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
4.33 USD -1.59% Intraday chart for Inozyme Pharma, Inc. -5.46% +1.64%
Apr. 08 Transcript : Inozyme Pharma, Inc. - Special Call
Apr. 08 Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency CI

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 267M
Net income 2024 * -94M Net income 2025 * -119M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-3 x
P/E ratio 2025 *
-2.75 x
Employees 59
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.34%
More Fundamentals * Assessed data

Chart Inozyme Pharma, Inc.

Dynamic Chart

Latest news about Inozyme Pharma, Inc.

Transcript : Inozyme Pharma, Inc. - Special Call
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency CI
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency CI
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions CI
Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency CI
Inozyme Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Insider Buy: Inozyme Pharma MT
Sector Update: Health Care Stocks Rising Late Friday MT
Sector Update: Health Care MT
Inozyme Pharma Prices $60 Million Share Offering MT
Sector Update: Health Care Stocks Declining Late Wednesday MT
Sector Update: Health Care Stocks Falling Wednesday Afternoon MT
Sector Update: Health Care MT
More news

Latest transcript on Inozyme Pharma, Inc.

Logo Inozyme Pharma, Inc.
Inozyme Pharma, Inc. - Special Call
More transcripts

Analyst Recommendations on Inozyme Pharma, Inc.

Jefferies Upgrades Inozyme Pharma to Buy From Hold, Adjusts Price Target to $6 From $4.50 MT
Wedbush Lowers Inozyme Pharma's Price Target to $15 From $20, Keeps Outperform Rating MT
Wedbush Adjusts Inozyme Pharma Price Target to $20 From $23, Maintains Outperform Rating MT
Jefferies & Co. Initiates Inozyme Pharma, Inc at Hold, Price Target Set at $5 MT
HC Wainwright Lowers Inozyme Pharma's Price Target to $20 From $33, Maintains Buy Rating MT
More recommendations

Press releases Inozyme Pharma, Inc.

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AQ
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference AQ
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 AQ
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights AQ
More press releases

Quotes and Performance

1 day-1.59%
1 week-5.46%
Current month-43.47%
1 month-30.50%
3 months-6.88%
6 months+49.83%
Current year+1.64%
More quotes

Highs and lows

1 week
4.18
Extreme 4.18
4.62
1 month
4.18
Extreme 4.18
7.80
Current year
4.03
Extreme 4.03
7.80
1 year
2.69
Extreme 2.689
7.80
3 years
0.99
Extreme 0.991
19.58
5 years
0.99
Extreme 0.991
31.65
10 years
0.99
Extreme 0.991
31.65
More quotes

Managers and Directors - Inozyme Pharma, Inc.

Managers TitleAgeSince
Axel Bolte FOU
 Founder 52 15-08-31
Doug Treco Treco CEO
 Chief Executive Officer 66 20-04-30
Sanjay Subramanian DFI
 Director of Finance/CFO 48 22-03-30
Members of the board TitleAgeSince
Doug Treco Treco CEO
 Chief Executive Officer 66 20-04-30
Reinaldo Diaz BRD
 Director/Board Member 70 16-12-31
Axel Bolte FOU
 Founder 52 15-08-31
More insiders

ETFs positioned on Inozyme Pharma, Inc.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.22% -
More ETFs positioned on Inozyme Pharma, Inc.

Quotes

Date Price Change Volume
24-04-25 4.33 -1.59% 627,485
24-04-24 4.4 0.00% 478,912
24-04-23 4.4 +0.23% 742,573
24-04-22 4.39 -2.66% 813,172
24-04-19 4.51 -1.53% 591,071

Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT

More quotes

Company Profile

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
Sector
Biotechnology & Medical Research
Calendar
2024-05-06 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.33 USD
Average target price
20.33 USD
Spread / Average Target
+369.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INOZYME PHARMA, INC. Stock Inozyme Pharma, Inc.
+1.64% 267M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+47.53% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 11.7B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.05B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. INZY Stock